Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates
Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks that will double in 2026.
Cullinan Therapeutics Inc. (CGEM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lynx1 Capital Management Weston Nichols | 8,963,500 | $92,772,225 | +56% | 18.78% |
| 2. | BioImpact Capital Mpm Capital | 7,648,268 | $79,159,574 | 9.06% | |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,750,683 | $59,519,569 | 2% | |
| 4. | Kynam Capital Derrick Tang | 3,114,132 | $32,231,266 | +36% | 2.06% |
| 5. | Siren L.L.C. Raymond Debbane | 1,193,410 | $12,351,794 | 0.37% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.40 | 165,667 | $1,391,685.63 | 8,963,500 | 2025-10-28 | Filing | |
| $7.84 | 32,217 | $252,565.17 | 8,797,833 | 2025-10-17 | Filing | |
| $8.86 | 150,000 | $1,328,250.00 | 8,765,616 | 2025-10-16 | Filing | |
| $7.94 | 51,500 | $409,049.05 | 8,615,616 | 2025-10-15 | Filing | |
| $7.59 | 15,032 | $114,047.78 | 8,564,116 | 2025-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.62 | 4,982 | $67,854.84 | 164,550 | 2026-02-20 | Filing | |
| $14.30 | 8,000 | $114,400.00 | 181,977 | 2026-02-20 | Filing | |
| $13.62 | 3,742 | $50,966.04 | 181,977 | 2026-02-20 | Filing | |
| $13.62 | 3,742 | $50,966.04 | 131,690 | 2026-02-20 | Filing | |
| $13.62 | 16,381 | $223,109.22 | 404,318 | 2026-02-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,400,296 | $45,543,064 | 0% | |
| 2. | 3,298,504 | $34,139,516 | 0% | |
| 3. | 2,350,972 | $24,332,560 | 7.51% | |
| 4. | 2,197,338 | $22,742,448 | 0% | |
| 5. | 1,932,106 | $19,997,297 | 1.14% |
News See All
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer
Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks under $10 to buy now. On July 22, Taiho Oncology Inc.
10 Stocks Under $10 to Buy Now
Earlier on July 1, Peter Kraus, Aperture Investors chairman and CEO, joined 'Squawk Box' on CNBC to suggest that the small and mid-cap area is a place for significant growth.
13 Best Booming Stocks to Buy Right Now
Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market turbulence and issuing highly positive outlook for the...
5 Most Undervalued Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to analysts.
12 Cheap Healthcare Stocks to Buy in 2023
The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades.
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds.
11 Cheap Value Stocks to Buy According to Seth Klarman
In this article, we discuss the 11 cheap value stocks to buy according to Seth Klarman.
Do Hedge Funds Love Cullinan Oncology, Inc. (CGEM)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Fund Resource Center